The Aenova Group has reached an agreement to acquire the Temmler Group, an international pharmaceutical company and full-service provider for pharmaceutical contract manufacturing. The Group has seven production sites in Germany, Switzerland, Italy and Ireland, with approximately 1000 employees and a turnover of approximately EUR 170 million. Financial terms were not disclosed. The acquisition, subject to certain requirements, is expected to close at the end of the year.
 
The Aenova Group provides services for the development, manufacture and commercialization of solid dosage forms. Heiner Hoppmann, chief executive officer of the Aenova Group, remarked, “The acquisition of the Temmler Group allows us to extend our position as European market leader. The portfolios of the two companies complement one another perfectly, as the Temmler Group produces dosage forms such as salves, gels and drops and is involved in new service segments, including the manufacture of clinical trial materials, distribution logistics and licensing.”
 
Dr. Werner Schneider, chief executive officer of the Temmler Group, added, “The planned integration into the Group gives Temmler an excellent perspective for the future and for the ongoing development of the business.”